Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

International Stem Cell (ISCO) Cash & Equivalents (2016 - 2025)

International Stem Cell (ISCO) has disclosed Cash & Equivalents for 16 consecutive years, with $966000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents fell 26.09% to $966000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $966000.0, a 26.09% decrease, with the full-year FY2024 number at $1.2 million, down 22.54% from a year prior.
  • Cash & Equivalents was $966000.0 for Q3 2025 at International Stem Cell, up from $920000.0 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $1.6 million in Q4 2023 to a low of $171000.0 in Q4 2021.
  • A 5-year average of $991000.0 and a median of $966000.0 in 2025 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: plummeted 75.18% in 2021, then skyrocketed 333.92% in 2022.
  • International Stem Cell's Cash & Equivalents stood at $171000.0 in 2021, then surged by 333.92% to $742000.0 in 2022, then soared by 114.02% to $1.6 million in 2023, then fell by 22.54% to $1.2 million in 2024, then dropped by 21.46% to $966000.0 in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Cash & Equivalents are $966000.0 (Q3 2025), $920000.0 (Q2 2025), and $1.5 million (Q1 2025).